Literature DB >> 9928880

Alteration in L-DOPA evoked dopamine and DOPAC output under conditions of impaired vesicular dopamine storage.

K Xu1, D E Dluzen.   

Abstract

We examined the effect of L-dihydroxyphenylalanine (L-DOPA) infusion in vitro upon dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) output from superfused corpus striatum of vehicle and reserpine or tetrabenazine (TBZ) treated male rats. Specifically, we tested the effects of two 20-min infusions of L-DOPA (5 uM) upon DA and DOPAC output (pg/mg/min) in reserpine (5 mg/kg, i.p., 24 hours before sacrifice; n=11), TBZ (30 mg/kg, i.p. 1 hour before sacrifice; n=8) or vehicle (n=21) treated rats. There was an overall significantly higher L-DOPA evoked DA output from the vehicle (12.22+/-1.74) versus reserpine (4.39+/-2.40) (p < 0.05), but not TBZ (9.16+/-2.81) treated rats. In addition, the DA response to the second L-DOPA infusion was significantly increased over that of the first response in the vehicle (9.40+/-2.11 vs. 15.04+/-2.78) (p < 0.05), but not reserpine or TBZ treated rats. The overall DOPAC outputs did not achieve a statistically significant difference among all treatment groups. However, the DOPAC outputs following the second L-DOPA infusion were significantly reduced in reserpine (41.15+/-6.10 vs. 20.27+/-4.54) and TBZ (21.38+/-4.41 vs. 10.87+/-2.36) (both p < 0.05), but not vehicle (28.99+/-4.00 vs. 24.91+/-4.78) treated rats. We conclude that: 1) the storage capacity of DA neurons is one of the important elements involved in affecting L-DOPA's effects upon DA and DOPAC output, 2) the shunting of storage to metabolism may represent a common characteristic in impaired nigrostriatal dopaminergic system, and 3) TBZ may operate differently from reserpine in the nigrostriatal dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9928880     DOI: 10.1007/s007020050114

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  2 in total

1.  Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Authors:  L Brusa; A Orlacchio; A Stefani; S Galati; M Pierantozzi; C Iani; N B Mercuri
Journal:  Funct Neurol       Date:  2013 Apr-May

2.  Measurement of urinary catecholamines in small samples for mice.

Authors:  Emily A Smith; Abigail L Schwartz; James B Lucot
Journal:  J Pharmacol Toxicol Methods       Date:  2012-09-07       Impact factor: 1.950

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.